Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
Unlike previous generations of software that primarily addressed low-level, sequential tasks that could be robotically executed, new cognitive architectures enable AI agents to dynamically automate end-to-end processes.
We’re thrilled to lead OfferFit’s Series B and believe it delivers a category-disrupting solution at a time when the marketing world is looking to embrace AI.
There’s been a seismic shift in the environment for learning and training on the job.
Tackling climate change and creating a more sustainable future is an enormous and overwhelming challenge—but our team at Menlo is motivated and optimistic.
In December of 2020, Menlo led the Series B investment in CodeSignal. Now, less than a year later, we’re doubling down in their Series C and welcoming Index Ventures to the team.
Across life sciences, a quality management system (QMS) is critical for both regulatory compliance and continuous product innovation.
We believe purpose-built vertical SaaS will help make drug discovery more effective and efficient and ultimately improve healthcare outcomes.
A very real concern emerging from the pandemic is the impact of remote learning on students who require more hands-on, personalized instruction.
There’s no doubt that the pandemic has created a landscape that will continue to encourage innovation and technological adoption.
H1 is a unique healthcare data SaaS company with proprietary data, compelling initial applications, and potential to expand.
The accelerated shift to digital has led to a surge in demand for developer talent as companies bolster their digital capabilities to respond, recover, and reimagine.
The adoption of cloud office platforms has exploded. With that growth came the sudden expansion of attack surfaces, which organizations are now forced to defend.
Today is a big day for Menlo Ventures as we’re adding our ninth partner, JP Sanday, who will focus on our Inflection Fund!